Anixa Biosciences is trading 11.05% higher at $3.09, with no confirmed catalyst for its October 23, 2026 move.
- A report noted CEO Amit Kumar purchased 8,000 shares at $2.72 on October 22, but does not establish that the purchase caused the rise.
- XBI fell 2.08% during the regular session, against a weaker biotech backdrop; sector movement does not explain the stock’s gain.